A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2017
At a glance
- Drugs BIIB 023 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Biogen
- 14 Apr 2016 This trial is prematurely ended in Belgium, Spain, Germany, Italy (end date: 8 Oct 2015), Poland (end date: 8 Oct 2015) and completed in Hungary ( 15 Jan 2016).
- 26 Oct 2015 Planned End Date changed from 1 Jan 2019 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 26 Oct 2015 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2015 as per ClinicalTrials.gov record.